Survival Following Stereotactic Radiotherapy for Recurrent High Grade Gliomas

Temel Bulgular & Veri:Ankara Onkoloji Hastanesinde, Temmuz 2009 ile Eylül 2012 tarihleri arasında yinelemiş 42 malign gliomlu (30 glioblastom, 12 anaplastik astrositom) hastaya Cyberknife (Accuray, Inc., Sunnyvale, CA, USA) ile stereotaktik radyoterapi uygulandı.

💡

Sonuç & Katkı:Yinelemiş glial tümürlü hastaların tedavisinde stereotaktik radyoterapi etkin bir seçenektir.

🔬Tür:Araştırma Makalesi

📍Kapsam:2009 · 42 hasta

⚙️Değişkenler:Alan Parametreleri

Özet

Yinelemiş yüksek gradlı glial tümörlü 42 hastada cyberknife deneyimimizi sunmaktayız. Ankara Onkoloji Hastanesinde, Temmuz 2009 ile Eylül 2012 tarihleri arasında yinelemiş 42 malign gliomlu (30 glioblastom, 12 anaplastik astrositom) hastaya Cyberknife (Accuray, Inc., Sunnyvale, CA, USA) ile stereotaktik radyoterapi uygulandı. Teşhisden sonraki ortanca takip zamanı 30 ay (aralık 8-144 ay), stereotaktik radyoterapi (SRT) sonrası ortanca takip zamanı 10 ay (aralık, 1-38 ay). Ortanca sağkalım, SRT sonrası glioblastom hastaları için 8 ay iken grade 3 gliomlu hastalar için 11 ay idi (p= 0.157). Stereotaktik radyoterapi sonrası ortanca sağkalım, kemoterapi alan hastalarda 9 ay iken almayanlarda 11 ay idi (p= 0.436). Nüks sonrası tekrar opere edilebilen hastalarda SRT sonrası ortanca sağkalım 10 ay iken opere edilemeyenlerde 9 ay bulundu( p= 0.827). Yinelemiş glial tümürlü hastaların tedavisinde stereotaktik radyoterapi etkin bir seçenektir.

Abstract

We aimed to report our stereotactic radiotherapy experience with Cyberknife (Accuray, Inc., Sunnyvale, CA, USA) for patients with recurrent high grade glial tumor. Forty-two patients with histologically proven malign glioma (30 glioblastoma, 12 anaplastic astrocytoma) and also treated with previous conventional fractioned radiotherapy underwent stereotactic radiotherapy via Cyberknife for their recurrent tumor in Ankara Oncology Hospital between July 2009-and September 2012. The median follow up time was 30 months (range, 8-144 months) after diagnosis and 10 months (range, 1-38 months) from stereotactic radiotherapy (SRT). The median survival from SRT are 8 months for glioblastoma patients and 11 months for grade 3 malign glioma patients (p= 0.157). The median survival from SRT are 9 months and 11 months in patients given chemotherapy and not given, respectively (p= 0.436). The median survival from SRT are 10 months in patients reoperated and 9 months not reoperated ( p= 0.827). Stereotactic radiotherapy is an effective treatment modality in patients with recurrent glial tumor.

🔖

Bu Makaleye Atıf Yap

ERTAŞ, G., UCER, A. R., GUNEY, Y. Y., AVCI, G. G., ALTUNDAG, M. B., ABANUZ, H., DEMIRKASIMOGLU, A., ÇALIKOĞLU, T. (2014). Survival Following Stereotactic Radiotherapy for Recurrent High Grade Gliomas. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 24 - Sayı: 4, 233–238. https://ajindex.com/articles/322877

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23: 2372-2377, 2005. Stewart LA. Chemotherapy in adult high grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
Stupp R, Mason VP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvan temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
Walker MD, Green SB, Byar DP, et al. Randomised comparisons of radiotherapy and nitrosoueras for the treatment malignant glioma after surgery. N Engl J Med 303: 1323-1329, 1980.
Pouration N, Crowlwy RW, Sherman JH, et al. Gama Knife radiorurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol 94: 409-418, 2009.
Biswas T, Okunieff P, Schell MC, et al. Stereotactic radiosurgery for glioblastoma:retrospective analysis. Radiat Oncol 17: 4-11, 2009.
Sanghavi S, Skrupsky R, Badie B. Recurrent malign gliomas treated with radiosurgery. J Radiosurg 2: 119-125, 1999.
Villavicencio AT, Burneikiene S, Romanelli P, et al. Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme. Neurosurg Rev 32: 417- 424, 2009.
Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008-1012, 1995.
Hess KR, Wong HT, Jaeckle KA, et al. Response and progression in recurrent malign glioma. Neurooncol 1: 282-288, 1999.
Nieder C, Grosu AL, Molls M et al. A comparison of treatment results for recurrent malign gliomas. Cancer Treat Rev 26: 397-409, 2002.
Niede C, Wiedenmann N, Andratschke, et al. Current status of angiogenesis inhibitors combined with radiotherapy. Cancer Treat Rev 32: 348-364, 2006.
Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185: 235-240, 2009.
Romanelli P, Conti A, Ponteriero A, et al. Role of stereotactic radiosurgery and fractioned stereotactic radiotherpy for the treatment of recurrent GBM. Neurosurg Focus 27: E8, 2009.
Kong DS, Lee JI, Park K, et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malig